Todas as fotos(1)

Documentos Principais

E1830000

Etamsylate

Name: Etamsylate
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Cyclonamine

Faça loginpara ver os preços organizacionais e de contrato

Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):

C₁₀H₁₇NO₅S

Número CAS:

2624-44-4

Peso molecular:

263.31

Código UNSPSC:

41116107

NACRES:

NA.24

Produtos recomendados

Slide 1 of 1

1 of 1

Supelco

PHR1048

4-Hydroxybenzoic acid

grau

pharmaceutical primary standard

família API

etamsylate

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

InChI

1S/C6H6O5S.C4H11N/c7-4-1-2-5(8)6(3-4)12(9,10)11;1-3-5-4-2/h1-3,7-8H,(H,9,10,11);5H,3-4H2,1-2H3

chave InChI

HBGOLJKPSFNJSD-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Etamsylate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Effect of the phytotherapeutic agent Eviprostat on 17beta-estradiol-induced nonbacterial inflammation in the rat prostate.

Michiko Oka et al.

The Prostate, 69(13), 1404-1410 (2009-06-03)

Anti-inflammatory medications have been used for the treatment of chronic prostatitis. The phytotherapeutic agent Eviprostat, a popular treatment for benign prostatic hyperplasia in Japan and Germany, has antioxidant and anti-inflammatory activity. We investigated the effects of the phytotherapeutic agent Eviprostat

Conventional and first derivative synchronous fluorometric determination of ethamsylate in pharmaceutical preparations and biological fluids. Application to stability studies.

Fathalla Belal et al.

Journal of fluorescence, 21(4), 1371-1384 (2011-02-25)

Two simple, accurate and highly sensitive spectrofluorometric methods were developed for the determination of ethamsylate (ETM). Method I is based on measuring the native fluorescence of ethamsylate in water at 354 nm after excitation at 302 nm. The calibration plot

Effect of the phytotherapeutic agent eviprostat on the bladder in a rat model of bladder overdistension/emptying.

Yuko Kawai et al.

Neurourology and urodynamics, 32(7), 1031-1037 (2012-11-13)

Ischemia-reperfusion injury is an important factor in the development of lower urinary tract symptoms (LUTS) that is partly mediated by the generation of free radicals. We investigate the effect of the phytotherapeutic agent Eviprostat, a treatment for benign prostatic hyperplasia

Effect of the phytotherapeutic agent Eviprostat on inflammatory changes and cytokine production in a rat model of nonbacterial prostatitis.

Hiroyuki Tsunemori et al.

Urology, 77(6), 1507-1507 (2011-06-01)

To examine the effect of the phytotherapeutic agent Eviprostat on the stromal-to-epithelial (S/E) ratio, level of macrophage infiltration, expression of the macrophage inhibitory cytokine-1 (Mic1) gene, and tumor necrosis factor-alpha (TNF-α) and interleukin-8 (IL-8) concentrations in prostate tissues in a

Eviprostat suppresses urinary oxidative stress in a rabbit model of partial bladder outlet obstruction and in patients with benign prostatic hyperplasia.

Seiji Matsumoto et al.

Phytotherapy research : PTR, 24(2), 301-303 (2009-07-09)

Eviprostat is a phytotherapeutic agent that has been used widely for more than 40 years in the treatment of benign prostatic hyperplasia (BPH) in Japan and Germany, and is known to have antioxidant activity. The present study investigated the effect

Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica